Platform

Nutraceuticals

Cosmetics

Standards

Request a Sample Pack

Platform

Nutraceuticals

Cosmetics

Standards

Request a Sample Pack

NUTRACEUTICAL INGREDIENT · US MARKET

LONGEVITY

BLACK GINSENG CORE™

Rare ginsenosides + NMN · patent pending

A two-part ingredient for the SIRT1 and NAD⁺ axis: Botalys black ginseng, steam-converted so that more than 80% of its ginsenosides are rare forms, paired with β-NMN, a precursor of NAD⁺.

Positioned for healthy aging, for the US market. The combination has not been tested in a clinical trial yet; each component has its own published data, shown below.

700 MG

Daily dose

20 MG

Rare ginsenosides a day

500 MG

NMN a day

Korean ginseng root illustration

What is it

TWO INPUTS, ONE ENZYME

TWO INPUTS, ONE ENZYME

SIRT1 is a NAD⁺-dependent enzyme involved in DNA repair, autophagy, mitochondrial function and inflammatory signalling. Its activity depends on two things: how much of the enzyme the cell makes, and how much NAD⁺ is available to run it. NAD⁺ levels decline with age.

Black Ginseng Core addresses both. Its ginseng component supplies rare ginsenosides such as Rg5, Rk1 and Rg3, which raised SIRT1 expression or activity in published cell and animal studies. Its NMN component supplies the NAD⁺ precursor, which raised blood NAD⁺ in human trials. The ginseng is the same aseptically grown, steam-cooked root as Red Ginseng HRG80™.

COMPOSITION

GINSENG + NMN

GINSENG

200 MG/DAY

STATUS

PATENT PENDING

MARKET

UNITED STATES

WHAT EACH COMPONENT DOES

WHAT EACH COMPONENT DOES

NAD⁺ SUPPLY

Oral NMN raised blood NAD⁺ versus placebo in a randomized, double-blind trial in 80 healthy adults aged 40 to 65, at 300, 600 and 900 mg a day, with the highest levels at 600 and 900 mg. The 500 mg in this formula sits inside that range.

HUMAN EVIDENCE, NMN

STRONG

Several randomized trials on NMN, not on this formula

SIRT1 EXPRESSION

Rare ginsenosides Rg3 and Rg5 increased SIRT1 expression or activity in cell and animal models of oxidative, inflammatory and metabolic stress. This has not been measured in humans, nor on this ginseng.

PRECLINICAL EVIDENCE

EMERGING

Published studies on isolated ginsenosides

THE GINSENG, TESTED ALONE

Tested alone as HRG80™ at the same 200 mg daily dose, the ginseng component reduced perceived stress and negative affect and shortened planning time versus placebo in 149 moderately stressed adults over three weeks.

HUMAN EVIDENCE, GINSENG

STRONG

3 randomized, double-blind trials on the ginseng component

Grades describe each component’s own published data. STRONG, significant in two or more randomized, double-blind, controlled trials. MODERATE, in one such trial. EMERGING, preclinical data only. No trial has tested the combination yet.

BLACK GINSENG CORE: EACH COMPONENT, MEASURED ALONE

BLACK GINSENG CORE: EACH COMPONENT, MEASURED ALONE

NMN RAISES BLOOD NAD⁺ IN HEALTHY ADULTS

In a 60-day randomized, double-blind, placebo-controlled trial in 80 healthy adults aged 40 to 65, NMN at 300, 600 and 900 mg a day increased blood NAD⁺ at days 30 and 60 compared with placebo and with baseline. Levels were highest at 600 and 900 mg, and walking distance in the six-minute test improved versus placebo.

This is published work on NMN, not on Black Ginseng Core. Results across NMN trials are not uniform: another 60-day trial at 300 mg found no significant rise in blood NAD⁺.

Randomized, multicenter, double-blind, placebo-controlled, parallel groups. 80 healthy adults aged 40 to 65, 60 days.

Placebo or 300, 600 or 900 mg NMN once daily. Blood NAD⁺, six-minute walk test, SF-36, safety.

Blood NAD⁺ up versus placebo and baseline at days 30 and 60 in all NMN groups (p ≤ 0.001). No safety issues reported up to 900 mg a day.

Yi et al., GeroScience 2023. NCT04823260.

THE GINSENG COMPONENT AT THE SAME 200 MG

The ginseng in Black Ginseng Core was tested alone, as HRG80™, at 200 mg a day in 149 moderately stressed adults at UCLouvain. Over three weeks it reduced perceived stress and negative affect more than placebo and shortened planning time. This supports the ginseng component; it says nothing yet about the combination.

Randomized, double-blind, placebo-controlled, parallel groups. 149 adults aged 18 to 60 with moderate perceived stress, 142 analysed.

HRG80 200 mg/day or placebo for 21 days. PSS −4.3 vs −2.7 (p = 0.040); PANAS negative affect −2.6 vs −1.1 (p = 0.032).

Dormal et al., Nutrients 2025; 17: 955. NCT06414486.

MODE OF ACTION: TWO INPUTS, ONE ENZYME

MODE OF ACTION: TWO INPUTS, ONE ENZYME

Rare ginsenosides act on how much SIRT1 the cell makes and how active it is; NMN supplies the NAD⁺ it needs to run. The grey labels show where each link has been measured.

INPUTS, DAILY DOSE

RARE GINSENOSIDES

Rg5 · Rk1 · Rg3, 20 mg from 200 mg of ginseng

NMN

β-nicotinamide mononucleotide, 500 mg

WHAT EACH INPUT ACTS ON

SIRT1 expression and activity

cell and animal studies on isolated Rg3 and Rg5

From rare ginsenosides

→ DNA REPAIR · AUTOPHAGY · MITOCHONDRIAL FUNCTION · INFLAMMATORY SIGNALLING

Blood NAD⁺

human trials on NMN

From NMN

→ COFACTOR OF SIRT1

PROCESSES THAT DEPEND ON SIRT1

DNA REPAIR

AUTOPHAGY

MITOCHONDRIAL FUNCTION

INFLAMMATORY SIGNALLING

The roles of SIRT1 listed above are established cell biology. That Black Ginseng Core engages them in humans has not been measured yet.

THE RECORD: CLAIMS AND SUPPORTING EVIDENCE

THE RECORD: CLAIMS AND SUPPORTING EVIDENCE

THE RECORD: CLAIMS AND SUPPORTING EVIDENCE

This table separates what each component has shown on its own from what the formula has shown. The formula itself has no trial yet: that is the last row, stated as such.

Until a combined study exists, Black Ginseng Core rests on two independent bodies of evidence and on the established role of NAD⁺ in SIRT1 function. A formulator should present it that way, and so do we.

FORMULATION

WORKING WITH IT

WORKING WITH IT

DAILY DOSE

700 MG FULL DOSE

200 mg ginseng with 20 mg rare ginsenosides, plus 500 mg NMN.

200 MG GINSENG

The dose tested alone in the largest ginseng trial.

500 MG NMN

Inside the 300 to 900 mg range tested in NMN trials.

No study has tested the combination. In the EU the formula cannot be sold as is: NMN is not yet authorised as a novel food, and the first positive EFSA opinion (May 2026) covers up to 300 mg a day.

TAKE IT INTO A FORMULA

TAKE IT INTO A FORMULA

Samples, specifications and the US claims guide are available to qualified brands and formulators.

REQUEST A SAMPLE

REQUEST THE HEALTH CLAIMS MATRIX

KOREAN GINSENG
────────

RHODIOLA ROSEA
────────

SOCIAL
────────

••••••
SUPPORTED BY EU
The project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement N° 859096.

DISCLAIMER
This website is intended to provide general information to industry experts and Health professionals and is not designed for the general public. Since BOTALYS active ingredients are being marketed in multiple countries around the world, it is the responsibility of each of our customers to ensure that the use of the ingredient and any claim made in the labeling or advertising of the ingredient comply with the applicable rules and regulations.

BOTALYS makes the sourcing of rare medicinal plants both possible & sustainable through biomimetic indoor farming, allowing its customers to harness the full potential of biodiversity - all while preserving it.

BOTALYS S.A.
Avenue des Artisans 8 box 6
7822 Ghislenghien, Belgium
TIN: BE 0834.134.177
+32 (0) 68 33 18 08

BOTALYS, Inc.
8205 Mescalero Dr
Austin, TX 78736, USA
+1 (512) 6472578
info@botalys.com

Copyright © BOTALYS SA. All rights reserved.

KOREAN GINSENG
────────

RHODIOLA ROSEA
────────

SOCIAL
────────

••••••
SUPPORTED BY EU
The project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement N° 859096.

DISCLAIMER
This website is intended to provide general information to industry experts and Health professionals and is not designed for the general public. Since BOTALYS active ingredients are being marketed in multiple countries around the world, it is the responsibility of each of our customers to ensure that the use of the ingredient and any claim made in the labeling or advertising of the ingredient comply with the applicable rules and regulations.

BOTALYS makes the sourcing of rare medicinal plants both possible & sustainable through biomimetic indoor farming, allowing its customers to harness the full potential of biodiversity - all while preserving it.

BOTALYS S.A.
Avenue des Artisans 8 box 6
7822 Ghislenghien, Belgium
TIN: BE 0834.134.177
+32 (0) 68 33 18 08

BOTALYS, Inc.
8205 Mescalero Dr
Austin, TX 78736, USA
+1 (512) 6472578
info@botalys.com

Copyright © BOTALYS SA. All rights reserved.